

Regorafenib CORRECT


PRELIMINARY SCORE

CURATIVE



NON-CURATIVE

OS



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Regorafenib CORRECT

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

1




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers

Therapeutic Indication: Treatment of patients with mCRC who have been previously treated with, or are not considered candidates for, available therapies. These include fluoropyrimidine-based ChT, an anti-VEGF therapy and an anti-EGFR therapy

Experimental Arm: Regorafenib

Control Arm: Placebo



